# Kisspeptin-54 and IVF egg maturation

> Ripple Peptides on kisspeptin and IVF egg maturation — Ripple Peptides examines the kisspeptin-54 IVF trial in women at high OHSS risk, the maturation outcome and the limits of the safety observation.

**3**

A trial in women at high risk of ovarian hyperstimulation syndrome gives the signal a concrete task: egg maturation.

## The high-risk trial

A timed intervention has a concrete purpose in the IVF work: egg maturation. A [Phase 2 randomized trial in 60 women at high risk of OHSS](https://pubmed.ncbi.nlm.nih.gov/26192876/) tested subcutaneous kisspeptin-54 as an oocyte-maturation trigger during IVF. Oocytes are eggs; maturation was the event the investigators were trying to produce. OHSS means ovarian hyperstimulation syndrome, the complication under observation in this trial.

Selecting women at high risk makes the safety question especially relevant. In my opinion, that choice is the most persuasive feature of the design. The trial aimed at a defined event in a defined research population, which gives the result a firmer shape than a broad claim about improving fertility.

![An illustrated embryologist observes a culture dish through a stereo microscope.](images/embryology-workbench.webp)

*An imagined embryology workspace, illustrating the setting of egg-maturation research rather than a particular trial or laboratory.*

## Maturation and OHSS outcomes

In [that trial](https://pubmed.ncbi.nlm.nih.gov/26192876/), oocyte maturation occurred in 95% of women, and there was no case of moderate, severe or critical OHSS. Both observations deserve space. The maturation result addresses whether the trigger worked; the OHSS observation addresses an important complication in the women who were studied.

I read the absence of those OHSS cases as encouraging within this trial. A claim that the complication can never happen would travel beyond the observation. Equally, burying the maturation result under a generic caution would lose the reason the experiment was worth doing. The useful account retains the selected population and both outcomes together.

The study also reported live births. That finding matters, too. Egg maturation and a live birth answer distinct questions, and an egg-maturation percentage cannot serve as a birth rate.

## Cells collected during IVF

A [study involving 48 women undergoing IVF](https://pubmed.ncbi.nlm.nih.gov/29206944/) compared granulosa lutein cells after different maturation triggers. Cells from women triggered with kisspeptin-54 showed higher expression of steroidogenic genes than cells from women triggered with hCG or a GnRH agonist, without increased markers of OHSS.

This adds a cellular question to the clinical one. Gene expression concerns what the collected cells were doing; maturation and live birth concern other outcomes. I appreciate having both levels in the literature, provided the cellular observation retains its own scale. It cannot silently inherit the clinical meaning of the trial beside it.

## Clinical status reported in 2025

A [systematic review published in 2025](https://pubmed.ncbi.nlm.nih.gov/38265397/) identified 29 interventional clinical trials across kisspeptin's potential applications, using databases searched through Feb 2023. It described kisspeptin as pre-approval, with no regulatory-approved product. That is the status reported in this review, whose literature search has a stated endpoint.

The IVF experiment earns my enthusiasm through its specificity: a timed intervention, a maturation outcome and observation for a named complication in a high-risk group. Those features make it a compelling piece of research. They also give the finding boundaries that a general fertility claim would discard.

---

At Ripple Peptides I follow kisspeptin through the published experiments and argue over the consequences, with essays to think about rather than medical advice to act on.